Literature DB >> 21908616

IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.

Jian-Ping Guo1, Domenico Coppola, Jin Q Cheng.   

Abstract

Serine/threonine kinase Akt regulates key cellular processes such as cell growth, proliferation, and survival. Activation of Akt by mitogenic factor depends on phosphatidylinositol 3-kinase (PI3K). Here, we report that IKBKE (also known as IKKε and IKKi) activates Akt through a PI3K-independent pathway. IKBKE directly phosphorylates Akt-Thr308 and Ser473 independent of the pleckstrin homology (PH) domain. IKBKE activation of Akt was not affected by inhibition of PI3K, knockdown of PDK1 or mTORC2 complex. Further, this activation could be inhibited by Akt inhibitors MK-2206 and GSK690693 but not the compounds (perifosine and triciribine) targeting the PH domain of Akt. Expression of IKBKE largely correlates with activation of Akt in breast cancer. Moreover, inhibition of Akt suppresses IKBKE oncogenic transformation. These findings indicate that IKBKE is an Akt-Thr308 and -Ser473 kinase and directly activates Akt independent of PI3K, PDK1, and mTORC2 as well as PH domain. Our data also suggest that Akt inhibitors targeting the PH domain have no effect on the tumors in which hyperactive Akt resulted from elevated IKBKE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908616      PMCID: PMC3199486          DOI: 10.1074/jbc.M111.287433

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.

Authors:  Mary L Hixon; Luisa Paccagnella; Robert Millham; Raul Perez-Olle; Antonio Gualberto
Journal:  Rev Recent Clin Trials       Date:  2010-09

2.  MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Authors:  Hiroshi Hirai; Hiroshi Sootome; Yoko Nakatsuru; Katsuyoshi Miyama; Shunsuke Taguchi; Kyoko Tsujioka; Yoko Ueno; Harold Hatch; Pradip K Majumder; Bo-Sheng Pan; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

3.  IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κB.

Authors:  Hongyu Guan; Heng Zhang; Junchao Cai; Jueheng Wu; Jie Yuan; Jun Li; Zhengsong Huang; Mengfeng Li
Journal:  J Pathol       Date:  2010-11-23       Impact factor: 7.996

Review 4.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update.

Authors:  Craig W Lindsley
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

5.  TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.

Authors:  Yi-Hung Ou; Michael Torres; Rosalyn Ram; Etienne Formstecher; Christina Roland; Tzuling Cheng; Rolf Brekken; Ryan Wurz; Andrew Tasker; Tony Polverino; Seng-Lai Tan; Michael A White
Journal:  Mol Cell       Date:  2011-02-18       Impact factor: 17.970

6.  Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation.

Authors:  Kajsa Ericson; Christine Gan; Ian Cheong; Carlo Rago; Yardena Samuels; Victor E Velculescu; Kenneth W Kinzler; David L Huso; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-20       Impact factor: 11.205

7.  The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane.

Authors:  N Berndt; H Yang; B Trinczek; S Betzi; Z Zhang; B Wu; N J Lawrence; M Pellecchia; E Schönbrunn; J Q Cheng; S M Sebti
Journal:  Cell Death Differ       Date:  2010-05-21       Impact factor: 15.828

Review 8.  Cellular and molecular pathways linking inflammation and cancer.

Authors:  Chiara Porta; Paola Larghi; Monica Rimoldi; Maria Grazia Totaro; Paola Allavena; Alberto Mantovani; Antonio Sica
Journal:  Immunobiology       Date:  2009-07-17       Impact factor: 3.144

Review 9.  IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.

Authors:  Julia Bollrath; Florian R Greten
Journal:  EMBO Rep       Date:  2009-11-06       Impact factor: 8.807

10.  Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Authors:  Irene M Ghobrial; Aldo Roccaro; Fangxin Hong; Edie Weller; Nancy Rubin; Renee Leduc; Meghan Rourke; Stacey Chuma; Antonio Sacco; Xiaoying Jia; Feda Azab; Abdel Kareem Azab; Scott Rodig; Diane Warren; Brianna Harris; Lyuba Varticovski; Peter Sportelli; Xavier Leleu; Kenneth C Anderson; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

View more
  50 in total

Review 1.  PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

2.  AKT goes cycling.

Authors:  Kiran N Mahajan; Nupam P Mahajan
Journal:  Cancer Control       Date:  2014-07       Impact factor: 3.302

3.  Evidence for Pipecolate Oxidase in Mediating Protection Against Hydrogen Peroxide Stress.

Authors:  Sathish Kumar Natarajan; Ezhumalai Muthukrishnan; Oleh Khalimonchuk; Justin L Mott; Donald F Becker
Journal:  J Cell Biochem       Date:  2016-12-13       Impact factor: 4.429

4.  Glucose Metabolism Reprogrammed by Overexpression of IKKε Promotes Pancreatic Tumor Growth.

Authors:  Haseeb Zubair; Shafquat Azim; Sanjeev Kumar Srivastava; Aamir Ahmad; Arun Bhardwaj; Mohammad Aslam Khan; Girijesh Kumar Patel; Sumit Arora; James Elliot Carter; Seema Singh; Ajay Pratap Singh
Journal:  Cancer Res       Date:  2016-10-20       Impact factor: 12.701

5.  IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.

Authors:  Mihir Rajurkar; Kyvan Dang; Maite G Fernandez-Barrena; Xiangfan Liu; Martin E Fernandez-Zapico; Brian C Lewis; Junhao Mao
Journal:  Cancer Res       Date:  2017-01-09       Impact factor: 12.701

6.  Regulation of IKKε Expression by Akt2 Isoform.

Authors:  Soumya Krishnamurthy; Alakananda Basu
Journal:  Genes Cancer       Date:  2011-11

7.  TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation.

Authors:  Bart Everts; Eyal Amiel; Stanley Ching-Cheng Huang; Amber M Smith; Chih-Hao Chang; Wing Y Lam; Veronika Redmann; Tori C Freitas; Julianna Blagih; Gerritje J W van der Windt; Maxim N Artyomov; Russell G Jones; Erika L Pearce; Edward J Pearce
Journal:  Nat Immunol       Date:  2014-02-23       Impact factor: 25.606

8.  Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.

Authors:  Congwen Wei; Yuan Cao; Xiaoli Yang; Zirui Zheng; Kai Guan; Qiang Wang; Yanhong Tai; Yanhong Zhang; Shengli Ma; Ye Cao; Xiaoxing Ge; Changzhi Xu; Jia Li; Hui Yan; Youguo Ling; Ting Song; Lin Zhu; Buchang Zhang; Quanbin Xu; Chengjin Hu; Xiu-wu Bian; Xiang He; Hui Zhong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

9.  JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic.

Authors:  Bailing Chen; Jia Liu; Qingshan Chang; Kevin Beezhold; Yongju Lu; Fei Chen
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

10.  IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.

Authors:  Alicia Y Zhou; Rhine R Shen; Eejung Kim; Ying J Lock; Ming Xu; Zhijian J Chen; William C Hahn
Journal:  Cell Rep       Date:  2013-02-28       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.